High resolution deep mutational scanning of the melanocortin-4 receptor enables target characterization for drug discovery
Authors:
- Conor J. HowardCHConor J. Howard
- Nathan S. AbellNANathan S. Abell
- Beatriz A. OsunaBOBeatriz A. Osuna
- Eric M. JonesEJEric M. Jones
- Leon Y. ChanLCLeon Y. Chan
- Henry ChanHCHenry Chan
- Jonathan B. AsfahaJAJonathan B. Asfaha
- Joshua S. BloomJBJoshua S. Bloom
- Aaron R. CooperACAaron R. Cooper
- Andrew LiaoALAndrew Liao
Preprint
Abstract
Deep Mutational Scanning (DMS) is an emerging method to systematically test the functional consequences of thousands of sequence changes to a protein target in a single experiment. Because of its utility in interpreting both human variant effects and protein structure-function relationships, it holds substantial promise to improve drug discovery and clinical development. However, applications in this domain require improved experimental and analytical methods. To address this need, we report novel DMS methods to precisely and quantitatively interrogate disease-relevant mechanisms, protein-ligand interactions, and assess predicted response to drug treatment. Using these methods, we performed a DMS of the melanocortin-4 receptor (MC4R), a G protein-coupled receptor (GPCR) implicated in obesity and an active target of drug development efforts. We assessed the effects of >6,600 single amino acid substitutions on MC4R’s function across 18 distinct experimental conditions, resulting in >20 million unique measurements. From this, we identified variants that have unique effects on MC4R-mediated Gαs- and Gαq-signaling pathways, which could be used to design drugs that selectively bias MC4R’s activity. We also identified pathogenic variants that are likely amenable to a corrector therapy. Finally, we functionally characterized structural relationships that distinguish the binding of peptide versus small molecule ligands, which could guide compound optimization. Collectively, these results demonstrate that DMS is a powerful method to empower drug discovery and development.Keywords
All Related Versions
- Version 1, 2024-12-19, eLife preprints (Unconfirmed version)
- Published version: eLife, 13.
This publication has 86 references indexed in Scilit:
- Expanding Approved Patient Populations for Rare Disease Treatment Using In Vitro DataClinical Pharmacology & Therapeutics, 2021
- Human MC4R variants affect endocytosis, trafficking and dimerization revealing multiple cellular mechanisms involved in weight regulationCell Reports, 2021
- UCSF ChimeraX: Structure visualization for researchers, educators, and developersProtein Science, 2020
- Human Gain-of-Function MC4R Variants Show Signaling Bias and Protect against ObesityCell, 2019
- A Scalable, Multiplexed Assay for Decoding GPCR-Ligand Interactions with RNA SequencingCell Systems, 2019
- Multiplexed assays of variant effects contribute to a growing genotype–phenotype atlasHuman Genetics, 2018
- Pharmacological chaperones for the misfolded melanocortin-4 receptor associated with human obesityBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2017
- Variant Interpretation: Functional Assays to the RescueThe American Journal of Human Genetics, 2017
- Melanocortin-4 Receptor in Energy Homeostasis and Obesity Pathogenesis2013
- Identification of a novel series of benzimidazoles as potent and selective antagonists of the human melanocortin-4 receptorBioorganic & Medicinal Chemistry Letters, 2007